Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis
Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis
The study's primary endpoint of progression-free survival (PFS) was met at primary analysis, demonstrating pirtobrutinib was superior to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR), based on independent review committee (IRC) assessment.
該研究的主要終點爲無進展生存期（PFS），在首次分析中達成，顯示pirtobrutinib優於研究者選擇的idelalisib加rituximab（IdelaR）或bendamustine加rituximab（BR），評估基於獨立審查委員會（鐵貨）認可。
Today's updated results corresponding to the final prespecified analysis, demonstrate consistent improvement in PFS for patients treated with pirtobrutinib, with a reduction in risk of relapse, disease or death by 46% compared to IdelaR or BR.
今天更新的結果對應於最終預先指定的分析，顯示接受pirtobrutinib治療的患者在PFS上持續改善，與IdelaR或BR相比，復發、疾病或死亡的風險降低了46%。
Pirtobrutinib also demonstrated clinically meaningful improvements in other secondary endpoints such as investigator-assessed PFS (median PFS: 15.3 vs. 9.2 months.
Pirtobrutinib在其他次級終點上也表現出臨床上有意義的改善，例如研究者評估的PFS（中位PFS：15.3個月 vs. 9.2個月）。
譯文內容由第三人軟體翻譯。